---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-103150"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T13:49:47.993236+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Xilio Therapeutics announces 1-for-14 reverse stock split to regain Nasdaq compliance

## Summary
- Effective 5:00 p.m. ET on March 13, 2026; trading on split-adjusted basis starts March 16 under ticker XLO.
- Outstanding shares reduce from ~73.5M to ~5.2M; authorized shares and par value unchanged.
- Purpose is to increase per-share price to meet Nasdaq minimum $1.00 bid requirement.
- No fractional shares issued; stockholders receiving cash in lieu of fractional shares.
- Stockholders approved reverse split at Special Meeting held February 23, 2026; ratio set by Board.

## SEC filing metadata
- accession: 0001193125-26-103150
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 3.03, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000119312526103150/0001193125-26-103150-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000119312526103150/xlo-20260312.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-103150
- JSON: https://secwatch.observer/filing/0001193125-26-103150.json
- Plain text: https://secwatch.observer/filing/0001193125-26-103150.txt

## Source-grounded claims
- claim_id: e52caf3232930681e0ad73536264cbfa6f1dd56f
  claim: Xilio Therapeutics, Inc.: Filed a Certificate of Amendment to effect a 1-for-14 reverse stock split of common stock (effective 2026-03-13).
  evidence_excerpt: On March 12, 2026, Xilio Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment to the Company’s Restated Certificate of Incorporation, as amended (the “Certificate of Amendment”), with the Secretary of State of the State of Delaware, which will effect, as of 5:00 p.m. Eastern Time, on March 13, 2026 (the “Effective Time”), a 1-for-14 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company’s common stock, $0.0001 par value per share (the “Common Stock”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840233/000119312526103150/0001193125-26-103150-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.